在老年人中使用linezolid的安全概况:国家数据库分析分析
Olga Butranova1, Victoria Koval1, Sergey Zyryanov1,2
1Department of General and Clinical Pharmacology, Peoples' Friendship University of Russia Named After Patrice Lumumba (RUDN), Moscow, Russia.
The International journal of risk & safety in medicine
|November 21, 2025
概括
在老年人 (≥60岁) 中使用莱涅佐利德显示出严重的安全问题,特别是骨髓抑制,如血小板缩和贫血. 仔细监测对于这一群体来说至关重要,以有效地管理药物不良反应.
科学领域:
- 药物监督 药物监督 药物监督
- 老年医学 老年医学
- 传染性疾病 传染性疾病
背景情况:
- 利尼佐利德是抗耐性格拉姆阳性感染的关键抗生素.
- 老年人容易受到linezolid的不良药物反应 (ADRs).
- 现实世界对老年人线索利德安全性的数据有限.
研究的目的:
- 在60岁及以上的患者中,描述与linezolid相关的不良药物反应 (ADR).
- 为了确定这个人群中最常见和最重要的安全问题.
主要方法:
- 来自俄罗斯药监数据库的自发报告 (SR) 的回顾性分析 (2019年4月-2024年12月).
- 专注于60岁及以上的患者.
- 对ADRs的系统器官类 (SOCs) 和首选术语 (PTs) 的分析.
主要成果:
- 60岁以上的患者占所有SRs的19.9%.
- 最重要的器官系统类别包括血液和淋巴系统疾病 (24.4%) 和胃肠道疾病 (17.6%).
- 最常见的药物不良反应是血小板缺血 (7.9%),贫血 (7.2%),恶心 (4.3%),腹 (3.6%),吐 (3.6%),白血病 (3.6%).
结论:
- 莱涅佐利德诱导的骨髓抑制是老年患者 (≥60岁) 的首要安全问题.
- 这些发现强调了需要对接受linezolid的老年人进行警的实验室和临床监测.
- 在老年人群中,积极管理ADR对于安全有效的linezolid治疗至关重要.
相关概念视频
01:15Drug Dosing: Geriatric Patients
214
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
214
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
223
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
223
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
186
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
186
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
217
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
217
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
212
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
212
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180